Natural Killer Cells Therapeutics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028

Natural Killer Cells Therapeutics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028

The global natural killer cells therapeutics market size reached US$ 2.5 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 5.4 Billion by 2028, exhibiting a growth rate (CAGR) of 13.70% during 2022-2028.

Natural killer (NK) cells therapeutics target multiple pathogenic antigens with efficient cytotoxicity and reduce the risk of cytokine storms. They can be produced from a variety of sources without relying on patient-specific immune cells. At present, several strategies have been developed, such as ex vivo pre-conditioning with cytokines or small molecular drugs and engineering a chimeric antigen receptor (CAR) NK, which improve the efficacy of NK cells therapeutics. Moreover, researchers are focusing on maximizing the therapeutic effects of allogeneic NK cells through robust expansion, enhanced targeting, and extended persistence of potent immune cells. This can also help unleash a strong and sustained anti-cancer immune-mediated attack.

Natural Killer Cells Therapeutics Market Trends:
A significant rise in the number of individuals with cancer, infectious diseases, and liver disorders represents one of the primary factors fueling the market growth. This can be attributed to unhealthy dietary patterns, lack of physical activities, growing air pollution, and the increasing number of individuals consuming alcohol and tobacco products. Moreover, as the risk of developing cancer rises dramatically with age, the increasing geriatric population across the globe is acting as another growth-inducing factor catalyzing the demand for NK cells therapeutics. Apart from this, as the immune response of cancer patients is not adequate, health companies are developing novel methods and technologies to boost the immune response through allogeneic, off-the-shelf NK cell-based therapies. Furthermore, there is a rise in the number of clinical studies that focus on tumor-targeted antibody strategies to enhance the therapeutic benefit of NK-cell-based therapy while minimizing risks and toxicities. In addition, governing agencies of numerous countries are funding financial schemes for cancer patients, which is creating a favorable outlook for the market.

Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global natural killer cells therapeutics market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on therapeutics, application and end user.

Breakup by Therapeutics:

NK Cell Therapies
NK Cell Directed Antibodies

Breakup by Application:

Cancer
Gastrointestinal Diseases
Immunoproliferative Disorders
Others

Breakup by End User:

Hospitals
Research Centers and Institutes
Others

Breakup by Region:

North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa

Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Affimed GmbH, Bristol-Myers Squibb Company, Fate Therapeutics, Fortress Biotech Inc., Glycostem Therapeutics, Innate Pharma S.A., Kuur Therapeutics Inc. (Athenex Inc.), Nkarta Inc., Takeda Pharmaceutical Company Limited and Ziopharm Oncology Inc.

Key Questions Answered in This Report

1. What was the size of the global natural killer cells therapeutics market in 2022?
2. What is the expected growth rate of the global natural killer cells therapeutics market during 2023-2028?
3. What are the key factors driving the global natural killer cells therapeutics market?
4. What has been the impact of COVID-19 on the global natural killer cells therapeutics market?
5. What is the breakup of the global natural killer cells therapeutics market based on the therapeutics?
6. What is the breakup of the global natural killer cells therapeutics market based on the application?
7. What is the breakup of the global natural killer cells therapeutics market based on the end user?
8. What are the key regions in the global natural killer cells therapeutics market?
9. Who are the key players/companies in the global natural killer cells therapeutics market?